CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to assess the efficacy and safety of AZD2373 in participants diagnosed with APOL1-Mediated Kidney Disease...
Phase 2
Nashville, Tennessee, United States and 76 other locations
tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...
Phase 2, Phase 3
Nashville, Tennessee, United States and 330 other locations
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medici...
Phase 3
Nashville, Tennessee, United States and 102 other locations
injections given 12 weeks (-14 days to +28 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in ...
Phase 3
Nashville, Tennessee, United States and 87 other locations
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys...
Phase 2
Nashville, Tennessee, United States and 156 other locations
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Nashville, Tennessee, United States and 739 other locations
with end stage kidney disease (ESKD) undergoing maintenance dialysis....
Phase 2, Phase 3
Nashville, Tennessee, United States and 462 other locations
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN)....
Phase 3
Brentwood, Tennessee, United States and 5 other locations
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
Phase 1, Phase 2
Nashville, Tennessee, United States and 8 other locations
savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease...
Phase 3
Nashville, Tennessee, United States and 58 other locations
Clinical trials
Research sites
Resources
Legal